PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients
Status:
RECRUITING
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
This trial is a phase II clinical trial of the safety and efficacy of PD-1 antibody (Toripalimab) in combination with paclitaxel (albumin-bound type) and gemcitabine and PULSAR radiotherapy in patients with locally advanced unresectable pancreatic cancer and patients with only local recurrence after pancreatic cancer surgery, to observe the safety and efficacy of PD-1 antibody (Toripalimab) in combination with paclitaxel (albumin-bound type) and gemcitabine and PULSAR in the treatment of patients with locally advanced unresectable pancreatic cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Fudan University
Treatments:
130-nm albumin-bound paclitaxel DEAE-Dextran Drug Therapy Gemcitabine Immunotherapy Radiotherapy